WO2015191636A3 - Xanthine oxidase inhibitors and methods of use - Google Patents

Xanthine oxidase inhibitors and methods of use Download PDF

Info

Publication number
WO2015191636A3
WO2015191636A3 PCT/US2015/034971 US2015034971W WO2015191636A3 WO 2015191636 A3 WO2015191636 A3 WO 2015191636A3 US 2015034971 W US2015034971 W US 2015034971W WO 2015191636 A3 WO2015191636 A3 WO 2015191636A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
xanthine oxidase
oxidase inhibitors
inhibitors
xanthine
Prior art date
Application number
PCT/US2015/034971
Other languages
French (fr)
Other versions
WO2015191636A2 (en
Inventor
Changyi Chen
Jian-ming LU
Qizhi Yao
Original Assignee
Baylor College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine filed Critical Baylor College Of Medicine
Publication of WO2015191636A2 publication Critical patent/WO2015191636A2/en
Publication of WO2015191636A3 publication Critical patent/WO2015191636A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Xanthine oxidase inhibitors are provided, as well as compositions, methods for their use for treating disorders, mediated at least in part, by xanthine oxidase.
PCT/US2015/034971 2014-06-09 2015-06-09 Xanthine oxidase inhibitors and methods of use WO2015191636A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462009810P 2014-06-09 2014-06-09
US62/009,810 2014-06-09
US201462060515P 2014-10-06 2014-10-06
US62/060,515 2014-10-06

Publications (2)

Publication Number Publication Date
WO2015191636A2 WO2015191636A2 (en) 2015-12-17
WO2015191636A3 true WO2015191636A3 (en) 2016-03-10

Family

ID=54834545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/034971 WO2015191636A2 (en) 2014-06-09 2015-06-09 Xanthine oxidase inhibitors and methods of use

Country Status (1)

Country Link
WO (1) WO2015191636A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105753774A (en) * 2016-03-31 2016-07-13 常州大学 Synthesis method for 2-hydroxyl-3-nitro-4-formylpyridine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803225A (en) * 1983-12-06 1989-02-07 Fisons, Plc Dihydroxy-phenethylamino compounds useful as pharmaceuticals
US5399577A (en) * 1991-05-01 1995-03-21 Taiho Pharmaceutical Co., Ltd. Isoxazole derivatives and salts thereof
US6121303A (en) * 1992-10-23 2000-09-19 Orion-Yhtyma Oy Pharmacologically active catechol derivatives
US6169092B1 (en) * 1996-07-12 2001-01-02 Bayer Aktiengesellschaft 3-Ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803225A (en) * 1983-12-06 1989-02-07 Fisons, Plc Dihydroxy-phenethylamino compounds useful as pharmaceuticals
US5399577A (en) * 1991-05-01 1995-03-21 Taiho Pharmaceutical Co., Ltd. Isoxazole derivatives and salts thereof
US6121303A (en) * 1992-10-23 2000-09-19 Orion-Yhtyma Oy Pharmacologically active catechol derivatives
US6169092B1 (en) * 1996-07-12 2001-01-02 Bayer Aktiengesellschaft 3-Ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 5 December 2007 (2007-12-05), Database accession no. 22112903 *
LU ET AL.: "3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a Potent Inhibitor of Xanthine Oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout", BIOCHEM PHARMACOL., vol. 86, no. 9, 2013, pages 22 *

Also Published As

Publication number Publication date
WO2015191636A2 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
EP3481434A4 (en) Crispr/cas9-based compositions and methods for treating retinal degenerations
EP3496739A4 (en) Compositions and methods for treating pulmonary hypertension
EP3347469A4 (en) Methods and compositions for the treatment of glaucoma
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
EP3750907A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
EP3096617A4 (en) Compositions and methods for treating ocular diseases
EP3298140A4 (en) Compositions for treating pathological calcification conditions, and methods using same
MX2018006632A (en) Bicyclic inhibitors of pad4.
EP3204386A4 (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
EP3182977A4 (en) Compositions and methods to treat vision disorders
EP3182979A4 (en) Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
EP3134120A4 (en) Compositions and methods for treating cytokine-related disorders
EP3220906A4 (en) Compositions and methods for treating lysosomal disorders
EP3189036A4 (en) Compositions and methods for treating proliferation disorders
MX2018006700A (en) Aza-benzimidazole inhibitors of pad4.
EP3125908A4 (en) Compositions and methods for treating kidney disorders
EP3126004A4 (en) Methods and compositions for treating inflammatory disorders
EP3142664A4 (en) Compositions and methods for treating and diagnosing ocular disorders
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
EP3122872A4 (en) Compositions and methods for treating type 1 and type 2 diabetes and related disorders
MX2016014436A (en) Heterocyclyl-butanamide derivatives.
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
EP3352755A4 (en) Novel compositions and methods for treating or preventing dermal disorders
EP3186269A4 (en) Compositions, methods and kits for treating complement related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15805993

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15805993

Country of ref document: EP

Kind code of ref document: A2